Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (21-30 of 578) with videos related to

Pageof 58
Sort By:
The Lancet. Oncology|December 15, 2010
Should we screen for endometrial cancer?Ignace Vergote, Frédéric Amant, Dirk Timmerman
The Lancet. Oncology|July 20, 2010
Laparoscopic hysterectomy for early endometrial cancerIgnace Vergote, Frederic Amant, Patrick Neven
Gynecologic and Obstetric Investigation|December 18, 2004
Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancerIsabelle Cadron, Anders Jakobsen, Ignace Vergote
International Journal of Surgical Pathology|April 22, 2016
Mesonephric (Wolffian) Pseudoendometrioid Carcinoma of the Broad Ligament, Arising From a Papillary CystadenomaPhilippe Moerman, Frederic Amant, Ignace Vergote
Cancer|January 23, 2020
Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancerIgnace Vergote, Philipp Harter, Luis Chiva
The Lancet. Oncology|July 12, 2016
Combined modality adjuvant therapy for high-risk endometrial cancerAdriaan Vanderstichele, Patrick Neven, Ignace Vergote
Gynecologic Oncology Reports|January 28, 2017
Ovarian cancer and the immune systemThaïs Baert, Ignace Vergote, An Coosemans
The New England Journal of Medicine|April 6, 2018
Hyperthermic Intraperitoneal Chemotherapy in Ovarian CancerIgnace Vergote, Luis Chiva, Andreas du Bois
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2019
Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian CancerAndreas du Bois, Thaïs Baert, Ignace Vergote
The Breast Journal|May 6, 2004
The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal womenAman U Buzdar, Ignace Vergote, Richard Sainsbury
Pageof 58

Showing results (21-30 of 578) with videos related to

Sort By:
Pageof 58
The Lancet. Oncology|December 15, 2010
Should we screen for endometrial cancer?Ignace Vergote, Frédéric Amant, Dirk Timmerman
The Lancet. Oncology|July 20, 2010
Laparoscopic hysterectomy for early endometrial cancerIgnace Vergote, Frederic Amant, Patrick Neven
Gynecologic and Obstetric Investigation|December 18, 2004
Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancerIsabelle Cadron, Anders Jakobsen, Ignace Vergote
International Journal of Surgical Pathology|April 22, 2016
Mesonephric (Wolffian) Pseudoendometrioid Carcinoma of the Broad Ligament, Arising From a Papillary CystadenomaPhilippe Moerman, Frederic Amant, Ignace Vergote
Cancer|January 23, 2020
Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancerIgnace Vergote, Philipp Harter, Luis Chiva
The Lancet. Oncology|July 12, 2016
Combined modality adjuvant therapy for high-risk endometrial cancerAdriaan Vanderstichele, Patrick Neven, Ignace Vergote
Gynecologic Oncology Reports|January 28, 2017
Ovarian cancer and the immune systemThaïs Baert, Ignace Vergote, An Coosemans
The New England Journal of Medicine|April 6, 2018
Hyperthermic Intraperitoneal Chemotherapy in Ovarian CancerIgnace Vergote, Luis Chiva, Andreas du Bois
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2019
Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian CancerAndreas du Bois, Thaïs Baert, Ignace Vergote
The Breast Journal|May 6, 2004
The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal womenAman U Buzdar, Ignace Vergote, Richard Sainsbury
Pageof 58